A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-07

Study Completion Date

2024-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

NCT06721494

Methamphetamine Intoxication Methamphetamine Disorders Methamphetamine Abuse

RECRUITING PHASE2

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

NCT01603147

Methamphetamine Abuse

COMPLETED PHASE1

Open-Label Disulfiram for Methamphetamine Dependence

NCT00731133

Methamphetamine Dependence

COMPLETED PHASE1/PHASE2

Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers

NCT00656357

Cocaine Dependence

COMPLETED PHASE1/PHASE2

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

NCT00519259

Methamphetamine Dependence

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Use Disorders Methamphetamine Abuse Methamphetamine Intoxication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

6 participants received a single dose of 2.7 mg/kg (2.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes.

A diluted CS-1103 saline solution in an IV bag is used for drug administration.

Group Type EXPERIMENTAL

CS-1103

Intervention Type DRUG

CS-1103 for infusion

Cohort 2

6 participants received single dose of 8.0 mg/kg (7.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes.

A diluted CS-1103 saline solution in an IV bag is used for drug administration.

Group Type EXPERIMENTAL

CS-1103

Intervention Type DRUG

CS-1103 for infusion

Cohort 3

6 participants received a single dose of 16.0 mg/kg (15.1 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes.

A diluted CS-1103 saline solution in an IV bag is used for drug administration.

Group Type EXPERIMENTAL

CS-1103

Intervention Type DRUG

CS-1103 for infusion

Cohort 4

6 participants received a single dose of 19.0 mg/kg (17.9 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes.

A diluted CS-1103 saline solution in an IV bag is used for drug administration.

Group Type EXPERIMENTAL

CS-1103

Intervention Type DRUG

CS-1103 for infusion

Placebo

2 participants for each cohort were administered with placebo.

Total administered volume of saline matched administered volume for the corresponding CS-1103 solution in each cohort.

Group Type PLACEBO_COMPARATOR

Sterile Saline

Intervention Type DRUG

Sterile Saline for Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CS-1103

CS-1103 for infusion

Intervention Type DRUG

Sterile Saline

Sterile Saline for Injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male and/or female participants aged 18 to 55 years, inclusive.
2. A body mass index between 18.0 to 30.0 kg/m2, inclusive, and a minimum body weight of 50 kg.
3. Females must be of nonchildbearing potential.

Exclusion Criteria

1. Estimated glomerular filtration rate \<90 mL/min/1.73 m2
2. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting ECG, and any clinically important abnormalities in the 12-lead ECG
3. Current smokers, or those who have smoked or used nicotine products (including nicotine patches) within 1 month prior to dose administration.
4. History of alcohol abuse or excessive intake of alcohol

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes